Treat severe psoriasis (clinical
trials currently under way)
Provectus has developed
groundbreaking biotechnologies
to augment vaccine production and detect viruses (including
an innovative “virus hunter” method); preparing to spinout the subsidiary
that contains our novel over-the-counter skin care products;
and seeks to license patented technologies for therapeutic
and cosmetic medical devices.
August 18, 2008
Video of Professor Thompson's SCC2008 Presentation Now Available
A video of Prof. John Thompson's July 25th presentation at the
Sydney Cancer Conference 2008 is available for viewing. A transcript of the
presentation is also available.
July 23, 2008
Professor John Thompson Discusses PV-10 on PM Radio
In an interview appearing on PM, a radio program broadcast on Radio National and ABC Local Radio
in Australia, Professor John Thompson discusses his work with PV-10 for melanoma. A transcript and
audio recording of the interview is available on the PM website at
http://www.abc.net.au/pm/content/2008/s2311345.htm.
July 23, 2008
Business Update Conference Call Audio Available
A Business Update Conference Call was held July 22, 2008.
An audio recording of the Business Update is available below.
July 18, 2008
Professor Thompson to Outline Ground-breaking Clinical Trial of PV-10 at the Sydney Cancer Conference 2008
"One presentation not to be missed will be by Professor John Thompson," said Professor Richard Christopherson,
Chair of the SCC2008 Organising Committee.
July 14, 2008
RedChip Announces the 2008 Emerging Markets Investor Conference in New York City
RedChip's Emerging Markets Small-Cap Investor Conference will be held August 21, 2008. Provectus' presentation
will be given by Provectus CEO Craig Dees, Ph.D.
October 6, 2008
Provectus Lead Investigator Professor John F. Thompson Gives Update on PV-10 Phase 2 Study
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCThttp://www.pvct.com)
announced that that the interim safety analysis on the first 20 subjects in its phase 2 clinical trial for
the treatment of metastatic melanoma has been completed. PV-10 injection was well tolerated by this group, with
an adverse event profile similar to that observed in phase 1. In addition, long-term survival data for subjects
participating in the phase 1 trial were presented.
October 2, 2008
Provectus Lead Investigator Professor John F. Thompson Presents at "Perspectives in Melanoma XII" Conference
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCThttp://www.pvct.com)
announced that the lead investigator for its Phase 2 melanoma study, Professor John F Thompson, MD, today presented clinical data on PV-10 at the "Perspectives in Melanoma XII" meeting at The Hague, The Netherlands. Professor Thompson's presentation was entitled "PV-10 Chemoablation of cutaneous and subcutaneous metastatic melanoma."
September 29, 2008
Provectus Receives $1.1 Million from Warrant Conversions
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCThttp://www.pvct.com)
announced today that it has received approximately $1.1 million from the early conversion of some of its outstanding warrants.
The Company now has approximately $5 million cash on hand to fund operations.
September 9, 2008
Provectus Pharmaceuticals Inc. Will Present at the Wall Street Analyst Forum 19th Annual Analyst Conference
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCThttp://www.pvct.com)
today announced that Chairman and CEO, Craig Dees, Ph.D., will present at The Wall Street Analyst Forum 19th Annual Analyst Conference on Wednesday, September 10 at 11:50 a.m. Eastern time.
This conference will be held at The University Club in New York. It will also be webcast at
http://wsw.com/webcast/wsaf7/pvct.ob
August 26, 2008
Professor John F. Thompson to Present at Perspectives in Melanoma XII, Thursday October 2, 2008
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCThttp://www.pvct.com)
announced today that the Lead Investigator for its phase 2 melanoma study, Professor John F. Thompson, MD,
will present clinical data on PV-10 at the Perspectives in Melanoma XII meeting at The Hague, The Netherlands.
July 21, 2008
Provectus Pharmaceuticals to Hold Business Update Conference Call at 4:15 pm EDT, on Tuesday, July 22, 2008
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCThttp://www.pvct.com),
will hold a conference call to update the market on its business on Tuesday, July 22, 2008 at 4:15 pm Eastern Daylight Time.
